Marianna Cortese
Research Subjects
Research Interests
Marianna Cortese has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Kjetil Bjornevik
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
18 shared publications - Trond Riise
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
11 shared publications Alberto Ascherio
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
10 shared publications- Alberto Ascherio
Department of Nutrition Harvard T.H. Chan School of Public Health Boston Massachusetts USA
7 shared publications Kjell-Morten Myhr
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
7 shared publicationsEva-Maria Wicklein
Bayer AG, Berlin, Germany
4 shared publications
Latest Publications
- 13 July 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (7) , 794-802
Gestational Age as a Risk Factor for Neurodevelopmental Disabilities: Exploring Causal Pathways
Background: Early and late delivery are associated with increased risk of neurodevelopmental disabilities. Some experts emphasise direct causal effect, while others propose confounding by underlying pathologies. Objectives: We present detailed relative‐risk estimates for five major neurodevelopmental disabilities by strata of gestational age. Confounding is explored through sibling‐matched analyses and the relative risks of birth defects with gestational age. Methods: Using data from Norway's Medical Birth Registry and other national health registries for 2.9 million births in 1967–2019, we conducted a prospective cohort analysis assessing gestational‐age‐specific relative risks for cerebral palsy (CP), intellectual impairment, epilepsy, autism spectrum disorder (ASD), and attention deficit/hyperactivity disorder (ADHD). We used an analysis of sibship‐matched pairs to assess the role of unmeasured confounding by conditions that persist across successive pregnancies. We also compared these gestational‐age‐specific risk patterns with the corresponding risks of five birth defects present before delivery. Results: Multivariable‐adjusted relative risks (RRs) of all five neurodevelopmental disabilities were increased with early pre‐term delivery. Compared with births at 40 weeks, infants born at 23–27 weeks had RRs ranging from 2‐fold for ADHD (RR 2.2, 95% confidence interval [CI] 2.0, 2.5) to 50‐fold for CP (95% CI 44, 58). Relative risks for post‐term delivery (≥ 43 weeks) were smaller, ranging from 1.15 to 1.45. In sibship analyses, relative risks with pre‐term delivery were attenuated, suggesting the influence of unmeasured confounding. The relative risks of birth defects with preterm and post‐term delivery were similar to neurodevelopmental disabilities, showing that confounding alone can produce relative risks of the magnitude seen with neurodevelopmental disabilities. Conclusions: The effect of gestational age at birth on neurodevelopment is likely less—and perhaps much less—than suggested by the observed associations. Prevention of neurodevelopmental disabilities depends not just on interventions during and after delivery, but on identifying and intervening on prenatal causes of these disabilities.
- 13 July 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (7) , 794-802
Gestational Age as a Risk Factor for Neurodevelopmental Disabilities: Exploring Causal Pathways
Background: Early and late delivery are associated with increased risk of neurodevelopmental disabilities. Some experts emphasise direct causal effect, while others propose confounding by underlying pathologies. Objectives: We present detailed relative‐risk estimates for five major neurodevelopmental disabilities by strata of gestational age. Confounding is explored through sibling‐matched analyses and the relative risks of birth defects with gestational age. Methods: Using data from Norway's Medical Birth Registry and other national health registries for 2.9 million births in 1967–2019, we conducted a prospective cohort analysis assessing gestational‐age‐specific relative risks for cerebral palsy (CP), intellectual impairment, epilepsy, autism spectrum disorder (ASD), and attention deficit/hyperactivity disorder (ADHD). We used an analysis of sibship‐matched pairs to assess the role of unmeasured confounding by conditions that persist across successive pregnancies. We also compared these gestational‐age‐specific risk patterns with the corresponding risks of five birth defects present before delivery. Results: Multivariable‐adjusted relative risks (RRs) of all five neurodevelopmental disabilities were increased with early pre‐term delivery. Compared with births at 40 weeks, infants born at 23–27 weeks had RRs ranging from 2‐fold for ADHD (RR 2.2, 95% confidence interval [CI] 2.0, 2.5) to 50‐fold for CP (95% CI 44, 58). Relative risks for post‐term delivery (≥ 43 weeks) were smaller, ranging from 1.15 to 1.45. In sibship analyses, relative risks with pre‐term delivery were attenuated, suggesting the influence of unmeasured confounding. The relative risks of birth defects with preterm and post‐term delivery were similar to neurodevelopmental disabilities, showing that confounding alone can produce relative risks of the magnitude seen with neurodevelopmental disabilities. Conclusions: The effect of gestational age at birth on neurodevelopment is likely less—and perhaps much less—than suggested by the observed associations. Prevention of neurodevelopmental disabilities depends not just on interventions during and after delivery, but on identifying and intervening on prenatal causes of these disabilities.
- 10 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 818-828
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study
Background: Multiple sclerosis (MS) is increasingly recognized as having a prodromal phase, characterized by non-specific symptoms preceding demyelinating events, yet prospective, longitudinal assessments of relevant signs before the first MS symptom are lacking. Objectives: To investigate whether a wide range of signs and symptoms occurred more frequently in individuals who later developed MS than in the underlying cohort. Methods: We followed 113,876 women from the Nurses’ Health Study II with prospectively collected data on lifestyle, health indicators, and diet. We examined the trajectory of these factors relative to the date of first symptom in 336 incident MS cases compared with the underlying cohort. Results: Several medical conditions, including migraine, depression, urinary leakage, and restless legs syndrome, were more prevalent in individuals who subsequently developed clinical MS. For example, the prevalence of migraine surpassed the underlying cohort 9–10 years before onset and reached 22.8% versus 19.3% at the time of first symptom. Furthermore, a decline in physical activity, physical function, and vitality occurred years before the first MS symptoms. Dietary changes were less pronounced. Conclusion: Several health indicators deteriorated years before typical MS symptoms emerged, suggesting that MS is preceded by a prodromal phase characterized by both specific and non-specific symptoms.
- 10 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 818-828
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study
Background: Multiple sclerosis (MS) is increasingly recognized as having a prodromal phase, characterized by non-specific symptoms preceding demyelinating events, yet prospective, longitudinal assessments of relevant signs before the first MS symptom are lacking. Objectives: To investigate whether a wide range of signs and symptoms occurred more frequently in individuals who later developed MS than in the underlying cohort. Methods: We followed 113,876 women from the Nurses’ Health Study II with prospectively collected data on lifestyle, health indicators, and diet. We examined the trajectory of these factors relative to the date of first symptom in 336 incident MS cases compared with the underlying cohort. Results: Several medical conditions, including migraine, depression, urinary leakage, and restless legs syndrome, were more prevalent in individuals who subsequently developed clinical MS. For example, the prevalence of migraine surpassed the underlying cohort 9–10 years before onset and reached 22.8% versus 19.3% at the time of first symptom. Furthermore, a decline in physical activity, physical function, and vitality occurred years before the first MS symptoms. Dietary changes were less pronounced. Conclusion: Several health indicators deteriorated years before typical MS symptoms emerged, suggesting that MS is preceded by a prodromal phase characterized by both specific and non-specific symptoms.
- 26 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (7) , 696-710
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years
Background: Metabolic dysregulations have been reported in multiple sclerosis (MS), but it is unclear whether metabolic profiles at disease onset predict long-term outcomes. Objectives: We evaluated whether baseline metabolic profiles at MS onset could predict disease activity/progression over 5 years. Methods: This prospective study included 468 patients enrolled in the BENEFIT trial at first clinical episode who completed 5 years of follow-up. Untargeted metabolomic profiling of 545 metabolites was performed at baseline using liquid chromatography–mass spectrometry. Associations with clinical and radiological outcomes were assessed using regression models, and machine learning was applied to identify metabolic signatures of worse outcomes. Models were adjusted for demographic, clinical, and lifestyle covariates. Results: Distinct metabolomic signatures were associated with worse 5-year outcomes, including relapses, lesion volume, brain atrophy, and disability (Expanded Disability Status Scale (EDSS), multiple sclerosis functional composite (MSFC)). These signatures modestly improved outcome prediction beyond established predictors, with the largest gain for brain volume loss (area under the curve (AUC) = 0.68–0.86). Pathway analysis showed enrichment of nicotinate/nicotinamide, histidine, and arginine metabolism across several outcomes, with unsaturated fatty acid biosynthesis specifically with relapses. Conclusion: Metabolic profiles in early MS modestly improve the prediction of 5-year outcomes beyond clinical factors. Consistent enrichment across some pathways suggests potential biological relevance, warranting further investigation of individual metabolites.
- 26 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (7) , 696-710
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years
Background: Metabolic dysregulations have been reported in multiple sclerosis (MS), but it is unclear whether metabolic profiles at disease onset predict long-term outcomes. Objectives: We evaluated whether baseline metabolic profiles at MS onset could predict disease activity/progression over 5 years. Methods: This prospective study included 468 patients enrolled in the BENEFIT trial at first clinical episode who completed 5 years of follow-up. Untargeted metabolomic profiling of 545 metabolites was performed at baseline using liquid chromatography–mass spectrometry. Associations with clinical and radiological outcomes were assessed using regression models, and machine learning was applied to identify metabolic signatures of worse outcomes. Models were adjusted for demographic, clinical, and lifestyle covariates. Results: Distinct metabolomic signatures were associated with worse 5-year outcomes, including relapses, lesion volume, brain atrophy, and disability (Expanded Disability Status Scale (EDSS), multiple sclerosis functional composite (MSFC)). These signatures modestly improved outcome prediction beyond established predictors, with the largest gain for brain volume loss (area under the curve (AUC) = 0.68–0.86). Pathway analysis showed enrichment of nicotinate/nicotinamide, histidine, and arginine metabolism across several outcomes, with unsaturated fatty acid biosynthesis specifically with relapses. Conclusion: Metabolic profiles in early MS modestly improve the prediction of 5-year outcomes beyond clinical factors. Consistent enrichment across some pathways suggests potential biological relevance, warranting further investigation of individual metabolites.
- 30 December 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (5) , 385-392
Epigenetic ageing and the risk of Parkinson’s disease
Background: Estimators of biological age, such as epigenetic clocks, are promising biomarkers for neurological disorders where the risk significantly increases with age, such as Parkinson’s disease (PD). The purpose of this study was to prospectively investigate whether epigenetic age acceleration can predict PD risk, age at PD onset and time to phenoconversion. Methods: We conducted a prospective, nested case-control study within the Nurses’ Health Study, including participants who provided two blood samples before being diagnosed with PD. DNA methylation profiles were obtained from 75 individuals who developed PD, 79 individuals who developed prodromal features suggestive of PD and 154 age-matched controls. We estimated epigenetic age acceleration using six different epigenetic clocks (Horvath, Hannum, PhenoAge, GrimAge, DunedinPACE and the cortical epigenetic clock) and assessed their associations with PD risk, age at PD onset and time to PD onset. Results: Epigenetic age acceleration was not consistently associated with a higher PD risk, using estimates of biological ageing neither in the first sample (collected a median of 19 years before PD onset) nor in the second sample (collected a median of 8 years before PD onset). These results remained similar in multivariable models adjusted for smoking status, physical activity, body mass index, caffeine intake, alcohol intake and Mediterranean diet score. Furthermore, epigenetic age acceleration was not associated with earlier age at PD onset or time to PD phenoconversion. Conclusions: In our study, epigenetic clock-based biomarkers do not reliably predict PD risk, age at PD onset or time to PD phenoconversion.
- 30 December 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (5) , 385-392
Epigenetic ageing and the risk of Parkinson’s disease
Background: Estimators of biological age, such as epigenetic clocks, are promising biomarkers for neurological disorders where the risk significantly increases with age, such as Parkinson’s disease (PD). The purpose of this study was to prospectively investigate whether epigenetic age acceleration can predict PD risk, age at PD onset and time to phenoconversion. Methods: We conducted a prospective, nested case-control study within the Nurses’ Health Study, including participants who provided two blood samples before being diagnosed with PD. DNA methylation profiles were obtained from 75 individuals who developed PD, 79 individuals who developed prodromal features suggestive of PD and 154 age-matched controls. We estimated epigenetic age acceleration using six different epigenetic clocks (Horvath, Hannum, PhenoAge, GrimAge, DunedinPACE and the cortical epigenetic clock) and assessed their associations with PD risk, age at PD onset and time to PD onset. Results: Epigenetic age acceleration was not consistently associated with a higher PD risk, using estimates of biological ageing neither in the first sample (collected a median of 19 years before PD onset) nor in the second sample (collected a median of 8 years before PD onset). These results remained similar in multivariable models adjusted for smoking status, physical activity, body mass index, caffeine intake, alcohol intake and Mediterranean diet score. Furthermore, epigenetic age acceleration was not associated with earlier age at PD onset or time to PD phenoconversion. Conclusions: In our study, epigenetic clock-based biomarkers do not reliably predict PD risk, age at PD onset or time to PD phenoconversion.
- Open Access
MC1R loss-of-function is associated with accelerated Parkinson’s disease motor decline
Background: Melanocortin 1 receptor ( MC1R ) is a key regulator of pigmentation. Previous studies have linked MC1R loss-of-function variants to increased risk for Parkinson ’ s disease (PD); however, whether they are associated with PD progression remains unknown. Using data from the Parkinson ’ s Progression Markers Initiative (PPMI) cohort, we aimed to test whether MC1R loss-of-function variants, especially those previously associated with an increased risk of PD, are associated with PD progression and phenoconversion. Methods: We analyzed PD progression in 802 PPMI participants (n=185 sporadic PD, 220 MC1R PD (139 heterozygotes, 64 compound heterozygotes, 17 homozygotes), 84 LRRK2 PD, 43 GBA PD, 187 MC1R + LRRK2 PD, and 83 MC1R + GBA PD) with 13 years of motor, non-motor, and cognitive assessments alongside 5 years of dopamine transporter imaging using linear mixed-effects models adjusted for potential confounders. Additionally, we explored risk of phenoconversion in 45 prodromal participants (n=16 sporadic, 29 MC1R ) using time-to-event survival analysis. Results: Participants with MC1R PD exhibited a 23% faster rate of motor decline (p=0.035) than participants with sporadic PD. The R160W variant (n=43 carriers), previously associated with an increased risk of PD, exhibited the strongest association with motor decline (p=0.023). High penetrance variants exhibited a stronger association with motor decline than low penetrance variants. Further, stratifying by genotype revealed that homozygotes exhibited a stronger association with motor decline than heterozygotes. Participants with MC1R PD also exhibited a non-statistically significant 24% faster rate of non-motor decline (p=0.070) than participants with sporadic PD. The rate of change in MoCA and DAT-SPECT SBR was minimal in all groups. Although not statistically significant, prodromal participants with MC1R loss-of-function variants exhibited a 3.81-fold increased risk of phenoconversion compared to noncarriers (p=0.059). Interpretation: MC1R loss-of-function variants are associated with accelerated PD motor decline in the PPMI cohort. Together with previous biological findings from our group and others, these results highlight the potential role of MC1R in PD prognosis, warranting further validation and investigation into whether MC1R-targeted interventions may modify PD progression.
Open AccessMC1R loss-of-function is associated with accelerated Parkinson’s disease motor decline
Background: Melanocortin 1 receptor ( MC1R ) is a key regulator of pigmentation. Previous studies have linked MC1R loss-of-function variants to increased risk for Parkinson ’ s disease (PD); however, whether they are associated with PD progression remains unknown. Using data from the Parkinson ’ s Progression Markers Initiative (PPMI) cohort, we aimed to test whether MC1R loss-of-function variants, especially those previously associated with an increased risk of PD, are associated with PD progression and phenoconversion. Methods: We analyzed PD progression in 802 PPMI participants (n=185 sporadic PD, 220 MC1R PD (139 heterozygotes, 64 compound heterozygotes, 17 homozygotes), 84 LRRK2 PD, 43 GBA PD, 187 MC1R + LRRK2 PD, and 83 MC1R + GBA PD) with 13 years of motor, non-motor, and cognitive assessments alongside 5 years of dopamine transporter imaging using linear mixed-effects models adjusted for potential confounders. Additionally, we explored risk of phenoconversion in 45 prodromal participants (n=16 sporadic, 29 MC1R ) using time-to-event survival analysis. Results: Participants with MC1R PD exhibited a 23% faster rate of motor decline (p=0.035) than participants with sporadic PD. The R160W variant (n=43 carriers), previously associated with an increased risk of PD, exhibited the strongest association with motor decline (p=0.023). High penetrance variants exhibited a stronger association with motor decline than low penetrance variants. Further, stratifying by genotype revealed that homozygotes exhibited a stronger association with motor decline than heterozygotes. Participants with MC1R PD also exhibited a non-statistically significant 24% faster rate of non-motor decline (p=0.070) than participants with sporadic PD. The rate of change in MoCA and DAT-SPECT SBR was minimal in all groups. Although not statistically significant, prodromal participants with MC1R loss-of-function variants exhibited a 3.81-fold increased risk of phenoconversion compared to noncarriers (p=0.059). Interpretation: MC1R loss-of-function variants are associated with accelerated PD motor decline in the PPMI cohort. Together with previous biological findings from our group and others, these results highlight the potential role of MC1R in PD prognosis, warranting further validation and investigation into whether MC1R-targeted interventions may modify PD progression.
- 28 November 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (4) , 309-315
Vitamin D intake and multiple sclerosis risk in the Norwegian Mother, Father and Child cohort
Background: Higher vitamin D has consistently been associated with a lower multiple sclerosis (MS) risk, but some controversy remains about whether this is due to vitamin D itself or sunlight. Methods: We conducted a prospective study among women participating in the Norwegian Mother, Father and Child Cohort Study, recruited in 2002–2008 and followed until 2022. We identified incident MS cases through data linkage with the Norwegian MS Registry. Total vitamin D intake from food and supplements was obtained from validated food frequency questionnaires completed in pregnancy. We estimated HRs for MS and 95% confidence intervals (CI) using Cox regression. Results: Among 78 074 participants, 349 developed MS during follow-up. Their median daily vitamin D intake was 296 international units (IU) compared with 333 IU among women who did not develop MS. Higher total vitamin D intake was associated with a 42% lower MS risk (HR comparing top vs bottom quintile 0.58, 95% CI 0.38 to 0.89, p trend trend =0.02) and supplements (HR for ≥600 IU/day vs trend =0.01). Conclusions: In this prospective study, higher vitamin D intake was associated with lower MS risk in women living in Norway, where there is insufficient sun-induced vitamin D production during most of the year. This supports the hypothesis that vitamin D itself modifies MS risk.
- 28 November 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (4) , 309-315
Vitamin D intake and multiple sclerosis risk in the Norwegian Mother, Father and Child cohort
Background: Higher vitamin D has consistently been associated with a lower multiple sclerosis (MS) risk, but some controversy remains about whether this is due to vitamin D itself or sunlight. Methods: We conducted a prospective study among women participating in the Norwegian Mother, Father and Child Cohort Study, recruited in 2002–2008 and followed until 2022. We identified incident MS cases through data linkage with the Norwegian MS Registry. Total vitamin D intake from food and supplements was obtained from validated food frequency questionnaires completed in pregnancy. We estimated HRs for MS and 95% confidence intervals (CI) using Cox regression. Results: Among 78 074 participants, 349 developed MS during follow-up. Their median daily vitamin D intake was 296 international units (IU) compared with 333 IU among women who did not develop MS. Higher total vitamin D intake was associated with a 42% lower MS risk (HR comparing top vs bottom quintile 0.58, 95% CI 0.38 to 0.89, p trend trend =0.02) and supplements (HR for ≥600 IU/day vs trend =0.01). Conclusions: In this prospective study, higher vitamin D intake was associated with lower MS risk in women living in Norway, where there is insufficient sun-induced vitamin D production during most of the year. This supports the hypothesis that vitamin D itself modifies MS risk.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213905
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39-0.95) and 0.60 (95% CI 0.37-0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38-0.94) and 0.65 (95% CI 0.43-0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213905
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39-0.95) and 0.60 (95% CI 0.37-0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38-0.94) and 0.65 (95% CI 0.43-0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213783
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course. This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders. The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid). Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213783
Open AccessAssociation of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course. This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders. The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid). Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
- 4 July 2025
- Published by Springer Nature
- p. 1-27
EBV and Autoimmunity
Although the role of Epstein-Barr virus (EBV) in autoimmunity is biologically plausible and evidence of altered immune responses to EBV is abundant in several autoimmune diseases, inference on causality requires the determination that disease risk is higher in individuals infected with EBV than in those uninfected and that in the latter it increases following EBV infection. This determination has so far been obtained compellingly for multiple sclerosis (MS) and, to some extent, for systemic lupus erythematosus (SLE). In contrast, evidence is either lacking or not supportive for other autoimmune conditions. In this chapter, we present the main epidemiological findings that justify these conclusions and their implications for prevention and treatment.
- 4 July 2025
- Published by Springer Nature
- p. 1-27
EBV and Autoimmunity
Although the role of Epstein-Barr virus (EBV) in autoimmunity is biologically plausible and evidence of altered immune responses to EBV is abundant in several autoimmune diseases, inference on causality requires the determination that disease risk is higher in individuals infected with EBV than in those uninfected and that in the latter it increases following EBV infection. This determination has so far been obtained compellingly for multiple sclerosis (MS) and, to some extent, for systemic lupus erythematosus (SLE). In contrast, evidence is either lacking or not supportive for other autoimmune conditions. In this chapter, we present the main epidemiological findings that justify these conclusions and their implications for prevention and treatment.
- 19 December 2024
- Published by Wiley in Annals of Neurology
- Vol. 97 (4) , 720-729
Identifying Individuals in the Prodromal Phase of Parkinson's Disease: A Prospective Cohort Study
Objective: We prospectively evaluated how well combinations of signs and symptoms can identify individuals in the prodromal phase of Parkinson's disease (PD).Methods: The study comprised 6,108 men who underwent repeated assessments of key prodromal features and were prospectively followed for the development of PD. Two composite measures of prodromal PD were evaluated: (i) the co‐occurrence of constipation, probable rapid eye movement (REM) sleep behavior disorder (pRBD), and hyposmia, and (ii) the probability of prodromal PD based on the Movement Disorders Society (MDS) research criteria. We also examined the progression and heterogeneity of the prodromal PD phase.Results: One hundred three individuals were newly diagnosed with PD over an average follow‐up of 3.4 years. Men with constipation, pRBD, and hyposmia had a 23‐fold higher risk of receiving a PD diagnosis in the subsequent 3 years, compared with men without these features (risk ratio [RR] = 23.35, 95% confidence interval [CI] = 10.62–51.33). The risk of PD was 21‐fold higher in men with a probability of prodromal PD ≥ 0.8 compared with those with a probability < 0.2 (RR = 21.96, 95% CI = 11.17–43.17). Both the co‐occurrence of the 3 non‐motor features and an MDS‐based probability ≥ 0.8 had comparable predictive values, and both were stronger predictors of PD than any of the features individually. We identified 2 prodromal PD subtypes where RBD and visual color impairment were key discriminators.Interpretation: Our study demonstrates that combinations of key signs and symptoms strongly predict future clinically manifest PD. These measures may be integrated into screening strategies to identify individuals who could be targeted for enrollment into PD prevention trials. ANN NEUROL 2025;97:720–729
- 19 December 2024
- Published by Wiley in Annals of Neurology
- Vol. 97 (4) , 720-729
Identifying Individuals in the Prodromal Phase of Parkinson's Disease: A Prospective Cohort Study
Objective: We prospectively evaluated how well combinations of signs and symptoms can identify individuals in the prodromal phase of Parkinson's disease (PD).Methods: The study comprised 6,108 men who underwent repeated assessments of key prodromal features and were prospectively followed for the development of PD. Two composite measures of prodromal PD were evaluated: (i) the co‐occurrence of constipation, probable rapid eye movement (REM) sleep behavior disorder (pRBD), and hyposmia, and (ii) the probability of prodromal PD based on the Movement Disorders Society (MDS) research criteria. We also examined the progression and heterogeneity of the prodromal PD phase.Results: One hundred three individuals were newly diagnosed with PD over an average follow‐up of 3.4 years. Men with constipation, pRBD, and hyposmia had a 23‐fold higher risk of receiving a PD diagnosis in the subsequent 3 years, compared with men without these features (risk ratio [RR] = 23.35, 95% confidence interval [CI] = 10.62–51.33). The risk of PD was 21‐fold higher in men with a probability of prodromal PD ≥ 0.8 compared with those with a probability < 0.2 (RR = 21.96, 95% CI = 11.17–43.17). Both the co‐occurrence of the 3 non‐motor features and an MDS‐based probability ≥ 0.8 had comparable predictive values, and both were stronger predictors of PD than any of the features individually. We identified 2 prodromal PD subtypes where RBD and visual color impairment were key discriminators.Interpretation: Our study demonstrates that combinations of key signs and symptoms strongly predict future clinically manifest PD. These measures may be integrated into screening strategies to identify individuals who could be targeted for enrollment into PD prevention trials. ANN NEUROL 2025;97:720–729